| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a36c66685971b78daf233b5999ead4c2 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07B2200-13 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-495
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5025
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-495
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D487-04 |
| filingDate |
2016-12-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6741b6aff20ff731549b0cf52826dc1b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5787608157a4def767c99699621ea616
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7c0137d5a50e014f1c7d4146a94e7892
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4d96140f132bbf195df813c6a2d29dbc |
| publicationDate |
2018-09-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-20180099787-A |
| titleOfInvention |
Crystalline forms of BTK kinase inhibitors and methods for their preparation |
| abstract |
The present invention relates to a crystalline form of a BTK kinase inhibitor and a process for its preparation. Specifically, the present invention relates to a process for preparing (R) -1- (3- (4-amino-3- (4- (2,6- difluorophenoxy) phenyl) -7- 2-alkane-1-ketone (compound of formula (I)) and a process for producing the same. BACKGROUND OF THE INVENTION [0002] . The I-form crystals of the compounds of formula (I) obtained by the present invention have excellent crystal stability and chemical stability, and the crystalline solvents used have low toxicity and residuals, and thus make them suitable for use in clinical treatment. |
| priorityDate |
2016-01-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |